<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308244">
  <stage>Registered</stage>
  <submitdate>17/07/2009</submitdate>
  <approvaldate>23/07/2009</approvaldate>
  <actrnumber>ACTRN12609000616279</actrnumber>
  <trial_identification>
    <studytitle>Intramuscular and intradermal hepatitis B vaccine administration: immunological response in hemodialysis patients</studytitle>
    <scientifictitle>In hemodialysis patients is intradermal vaccine administration as good or better than intramuscular vaccination for hepatitis B immunization?</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B vaccination</healthcondition>
    <healthcondition>Hemodialysis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intradermal Hepatitis B vaccine, 3 times 4 micrograms doses at 0, 1 and 2 months.</interventions>
    <comparator>Intramuscular Hepatitis B vaccine, 3 times 40 micrograms doses at 0, 1 and 2 months.</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Antibody titers to hepatitis B surface antigen (anti-HBs)</outcome>
      <timepoint>Timepoint: at baseline, 1, 2, 3, 4, 5 and 6 months after intervention commencement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients achieving immunizing titers of antibodies to hepatitis B antigen</outcome>
      <timepoint>At 6 months after intervention</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Incident chronic hemodialysis (HD) patients, with end-stage renal disease before completing the third month of HD treatment.</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Presence of  antibodies against aquired immunodeficiency virus, antibodies against hepatits C, previous hepatitis B vaccination, a reagent antibody titers to hepatitis B surface antigen (Anti-HBs &gt; 10 UI/mL).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Series of unidentified, identical and sealed envelopes with the information IM or ID, for intramuscular or intradermal vaccination</concealment>
    <sequence>Simple randomisation by using a raffle.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>2/08/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>198</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Rio Grande do Sul (RS)</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Nefrologia â€“ Faculdade de Medicina/Instituto de Pesquisas Biomedicas/Hospital Sao Lucas from PUCRS</primarysponsorname>
    <primarysponsoraddress>Dr Domingos dAvila
Nefrologia  Hospital Sao Lucas  Terceiro andar. 
Avenida Ipiranga 6690
Porto Alegre  RS   CEP 90610000</primarysponsoraddress>
    <primarysponsorcountry>Brazil</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname />
      <fundingaddress />
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Ana Elizabeth Prado Lima Figueiredo</othercollaboratorname>
      <othercollaboratoraddress>Nefrologia - Hospital Sao Lucas - Terceiro andar. 
Avenida Ipiranga 6690
Porto Alegre  RS   CEP 90610000</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Carlos Abaete de los Santos</othercollaboratorname>
      <othercollaboratoraddress>Nefrologia - Hospital Sao Lucas - Terceiro andar. 
Avenida Ipiranga 6690
Porto Alegre  RS   CEP 90610000</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Carlos Eduardo Poli de Figueiredo</othercollaboratorname>
      <othercollaboratoraddress>Nefrologia - Hospital Sao Lucas - Terceiro andar. 
Avenida Ipiranga 6690
Porto Alegre  RS   CEP 90610000</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Regina Helena Medeiros</othercollaboratorname>
      <othercollaboratoraddress>Nefrologia - Hospital Sao Lucas - Terceiro andar. 
Avenida Ipiranga 6690
Porto Alegre  RS   CEP 90610000</othercollaboratoraddress>
      <othercollaboratorcountry>Brazil</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Hepatitis B is a viral infection that may progress to cirrhosis and liver carcinoma. Its prevalence has been estimated at 4.9% among hemodialysis patients. The vaccine applied intramuscularly (IM) to end-stage kidney disease patients, often elicits inadequate antibody titers. Additionally, intradermal (ID) vaccine inoculation into healthy individuals and hemodialysis patients seems to be effective. 
The study compared the responses to the two vaccine application approaches, in patients initiating hemodialysis.
Hemodialysis patients were randomized to receive either 40 micrograms/dose IM vaccine or 4 micrograms/dose ID vaccine at zero, 1 and 2 months. Patients were followed for 6 months with evaluation of titers of antibodies against hepatitis B surface antigen (anti-HBs).</summary>
    <trialwebsite />
    <publication>1. Medeiros RH, Figueiredo AE, Poli de Figueiredo CE, d Avila D, de los Santos CA (2009) Intramuscular or intradermal hepatitis B vaccine administration in hemodialysis patients? American Journal of Kidney Diseases 54(5):981-982. doi:10.1053/j.ajkd.2009.07.024</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Comite de Etica em Pesquisas - PUCRS</ethicname>
      <ethicaddress>Hospital Sao Lucas da PUCRS
Avenida Ipiranga 6690
Porto Alegre  RS  CEP 90610000
Brazil</ethicaddress>
      <ethicapprovaldate>27/02/2003</ethicapprovaldate>
      <hrec>1/03/1472</hrec>
      <ethicsubmitdate />
      <ethiccountry>Brazil</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Domingos d'Avila</name>
      <address>Nefrologia  Hospital Sao Lucas - Terceiro andar.
Avenida Ipiranga 6690
Porto Alegre  RS   CEP 90610000
Brazil</address>
      <phone>+ 55 51 33367700</phone>
      <fax>+ 55 51 33367700</fax>
      <email>dominavila@pucrs.br</email>
      <country>Brazil</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Domingos d'Avila</name>
      <address>Nefrologia  Hospital Sao Lucas - Terceiro andar.
Avenida Ipiranga 6690
Porto Alegre  RS   CEP 90610000
Brazil</address>
      <phone>+ 55 51 33367700</phone>
      <fax>+ 55 51 33367700</fax>
      <email>dominavila@pucrs.br</email>
      <country>Brazil</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Domingos d'Avila</name>
      <address>Nefrologia  Hospital Sao Lucas - Terceiro andar.
Avenida Ipiranga 6690
Porto Alegre  RS   CEP 90610000
Brazil</address>
      <phone>+ 55 51 33367700</phone>
      <fax>+ 55 51 33367700</fax>
      <email>dominavila@pucrs.br</email>
      <country>Brazil</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>